Table 3 The exact situations in which biologics were utilized for JDM. Respondents could answer more than one time. Ten potential respondents did not choose any of the choices
After failing mtx | 5/94 5.3% |
After failing CS and mtx | 14/94 14.9% |
After failing CS, mtx, and IVIG | 39/94 41.5% |
After failing CS, mtx, IVIG, or IM (AZA, MMF, or CSA) | 48/94 51.1% |
Systemic JDM with internal organ involvement | 10/94 14.9% |
Severe ulcerative disease | 14/94 14.9% |
Other | 27/94 14.9% |